Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tracon Pharma (NQ: TCON )

1.680 -0.010 (-0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,444
Open 1.680
Bid (Size) 1.570 (1)
Ask (Size) 1.710 (20)
Prev. Close 1.690
Today's Range 1.630 - 1.700
52wk Range 1.101 - 2.900
Shares Outstanding 23,822,542
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
Earnings Scheduled For March 8, 2023
Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million. 
Via Benzinga

Performance

YTD
+15.86%
+15.86%
1 Month
-1.18%
-1.18%
3 Month
+28.74%
+28.74%
6 Month
-5.62%
-5.62%
1 Year
-41.26%
-41.26%

More News

Read More
A Preview Of TRACON Pharmaceuticals's Earnings
Via Benzinga
TRACON to Report Fourth Quarter and Year-End 2022 Financial Results and Provide Corporate Update on March 8, 2023
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
Runway Growth Finance Corp. Provides Fourth Quarter 2022 Portfolio Update
From Runway Growth Finance Corp.
Via Globe NewsWire
TRACON Pharmaceuticals Announces up to $30M Non-Recourse Non-Dilutive Financing Related to Arbitration Award Decision Expected in Q1 2023
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
TRACON Shares Ascend On FDA Fast Track Status To Soft Tissue Cancer Candidate
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
TRACON Touts Encouraging Objective Response Rates For Mid-Stage Cancer Study
Via Benzinga
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
Earnings Scheduled For November 14, 2022
Via Benzinga
TRACON Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
TRACON to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 14, 2022
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
$1.9 Million Bet On This Biotechnology Stock? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Week In Review: AIM Vaccine Stages $20 Million IPO On Hong Kong Exchange
Via Talk Markets
TRACON Pharmaceuticals And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
Via Benzinga
Runway Growth Finance Corp. Provides Third Quarter 2022 Portfolio Update
From Runway Growth Finance Corp.
Via Globe NewsWire
TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from ENVASARC Phase 2 Pivotal Trial - Trial to Proceed as Planned
From TRACON Pharmaceuticals, Inc.
Via Globe NewsWire
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
Via InvestorPlace
$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying
Via Benzinga
Cyclo Therapeutics, TRACON Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.